Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in systemic sclerosis with interstitial lung disease
ISRCTN99672071Phase 2Completed
- Sponsor
- University General Hospital of Patras
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in systemic sclerosis (SSc) (2 arms), sponsored by University General Hospital of Patras. Primary endpoints: Change in skin histology including collagen deposition and lymphocytic infiltration and Change in pulmonary function. Started Mar 2008; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ISRCTN99672071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99672071.